Bioresorbable Coronary Scaffolds: Deployment Tips and Tricks and the Future of the Technology
By: Jr. Costa and Alexandre Abizaid
References
- Serruys PW , Chevalier B , Dudek D , A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015 Jan 3; 385 9962: 43– 54.
- Ellis SG , Kereiakes DJ , Metzger DC , .; ABSORB III Investigators Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015 Nov 12; 373 20: 1905– 15.
-
Abizaid
A
,
Ribamar Costa
J
Jr , Bartorelli AL , ; ABSORB EXTEND investigators The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015 Apr; 10 12: 1396– 401. - Verheye S , Ormiston JA , Stewart J , A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014 Jan; 7 1: 89– 99.
- Abizaid A , Costa RA , Schofer J , Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. JACC Cardiovasc Interv. 2016 Mar 28; 9 6: 565– 74.
- Haude M , Ince H , Abizaid A , Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016 Jan 2; 387 10013: 31– 9.
- Stone GW , Gao R , Kimura T , 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016 Mar 26; 387 10025: 1277– 89.
- Lipinski MJ , Escarcega RO , Baker NC , Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. JACC Cardiovasc Interv. 2016 Jan 11; 9 1: 12– 24.
- Räber L , Brugaletta S , Yamaji K , Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. J Am Coll Cardiol. 2015 Oct 27; 66 17: 1901– 14.
- Capodanno D , Gori T , Nef H , Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015 Feb; 10 10: 1144– 53.
- Wöhrle J , Naber C , Schmitz T , Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention. 2015 Jun; 11 2: 149– 56.
- Kraak RP , Hassell ME , Grundeken MJ , Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention. 2015 Feb; 10 10: 1160– 8.
- Gori T , Schulz E , Hink U , Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes. JACC Cardiovasc Interv. 2015 May; 8 6: 770– 777.
- Cortese B , Ielasi A , Romagnoli E , Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions. Am J Cardiol. 2015 Sep 1; 116 5: 705– 10.
- Puricel S , Cuculi F , Weissner M , Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016 Mar 1; 67 8: 921– 31.
- Ishibashi Y , Nakatani S , Sotomi Y , Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015 Nov; 8 13: 1715– 26.
- Ortega-Paz L , Capodanno D , Gori T , Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017 Apr 20; 12 17: 2110– 2117.
- Danzi GB , Sesana M , Arieti M , Does optimal lesion preparation reduce the amount of acute recoil of the Absorbe BVS? Insights from a real-world population. Catheter Cardiovasc Interv. 2015 Nov 15; 86 6: 984– 91.
- Mattesini A , Secco GG , Dall'Ara G , ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv. 2014 Jul; 7 7: 741– 50.
- Brown AJ , McCormick LM , Braganza DM , Bennett MR , Hoole SP , West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv. 2014 Jul 1; 84 1: 37– 45.
- Onuma Y , Serruys PW , Muramatsu T , Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014 Dec; 7 12: 1400– 11.
- Sotomi Y , Suwannasom P , Serruys PW , Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017 Feb 20; 12 14: 1747– 56.
- Ormiston JA , Webber B , Ubod B , Darremont O , Webster MW. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015 May; 11 1: 60– 7.
- Caiazzo G , Kilic ID , Fabris E , Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience? Int J Cardiol. 2015 Dec 15; 201: 129– 36.
- Andrade JD Hlady V. Plasma Protein Absorption: The Big Twelve. In: Leonard EF , Turitto VT , Vroman I , editors. Blood in Contact with Natural and Artificial Surfaces: Annals of the New York Academy of Sciences. New York: New York Academy of Sciences; 1987. p. 153.
- Wang K. Biocompatibilisation of Coronary Artery Stents. Acta Biomedica Lovaniensia. 1997; 162: 89– 102.
- Steinemann SG. Metal implants and surface reactions. Injury. 1996; 27 Suppl 3: SC16– 22.
- de Scheerder I , Sohier J , Wang K. Metallic Surface Treatment Using Electrochemical Polishing Decreases Thrombogenicity and Neointimal Hyperplasia of Coronary Stents. J Interv Cardiol. 2000; 13: 179– 85.
- Cortese B Valgimigli M. Current know how on the absorb BVS technology: an experts' survey. Int J Cardiol. 2015 Feb 1; 180: 203– 5.
- Tamburino C , Latib A , van Geuns RJ , Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015 May; 11 1: 45– 52.
- Wiebe J , Bauer T , Dörr O , Möllmann H , Hamm CW , Nef HM. Implantation of a novolimuseluting bioresorbable scaffold with a strut thickness of 100 μm showing evidence of self-correction. EuroIntervention. 2015 Jun; 11 2: 204.
- Boeder NF , Koepp T , Dörr O , A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. Int J Cardiol. 2016 Oct 1; 220: 706– 10.
- CV Pipeline [Internet]. Santa Barbara, CA: Market Monitors, Inc.; c2018. Fantom, REVA Medical, Inc. [cited 2018 Jan 8]. Available from: https://www.cvpipeline.com/sectors/DES/products.
- Costa J , Abizaid A , Chamie D , Lansky A , Kochman J , Koltowski L. Initial results of the FANTOM 1 trial: a first-in-man evaluation of a novel, radiopaque sirolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2016; 67 13S: 232.
- Abizaid A , Carrié D , Frey N , .; FANTOM II Clinical Investigators 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study. JACC Cardiovasc Interv. 2017 Sep 25; 10 18: 1832– 8.
- Seth A , Onuma Y , Costa R , First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. EuroIntervention. 2017 Jul 20; 13 4: 415– 423.
DOI: https://doi.org/10.14797/mdcj-14-1-42 | Journal eISSN: 1947-6108
Language: English
Page range: 42 - 49
Published on: Jan 1, 2018
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2018 Jr. Costa, Alexandre Abizaid, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.